Original data (with adjusted standard errors for multi-arm studies):

              treat1      treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
2            placebo    zolpidem -0.2538 0.1316     0.1316     0.2007     2         
6        eszopiclone     placebo -0.3777 0.1024     0.1024     0.1829     2         
10           placebo    zolpidem  0.5490 0.1099     0.1099     0.1872     2         
12       eszopiclone     placebo -0.2751 0.4616     0.4616     0.4859     2         
39           placebo    zolpidem  0.4688 0.1521     0.1521     0.2147     2         
45           placebo  suvorexant  0.1539 0.0828     0.0828     0.1727     2         
46           placebo  suvorexant  0.2374 0.0864     0.0864     0.1745     2         
58       eszopiclone     placebo -0.1985 0.0825     0.0825     0.1726     2         
59           placebo    zolpidem  0.4893 0.0670     0.0670     0.1657     2         
60           doxepin     placebo -0.3861 0.1785     0.1785     0.2342     2         
61           doxepin     placebo  0.0219 0.1482     0.1482     0.2119     2         
63           doxepin     placebo -0.2470 0.1326     0.1326     0.2014     2         
75           placebo   ramelteon -0.1058 0.0942     0.0942     0.1785     2         
77       eszopiclone     placebo -0.1448 0.1255     0.1255     0.1968     2         
83  BZD-intermediate     placebo -1.0467 0.3606     0.3606     0.3912     2         
99      daridorexant    zolpidem -0.0748 0.1579     0.1822     0.2600     3        *
99           placebo    zolpidem  0.1866 0.1828     0.2588     0.3107     3        *
99      daridorexant     placebo -0.2614 0.1583     0.1829     0.2606     3        *
105          placebo    zolpidem  0.4374 0.1435     0.1435     0.2087     2         
112          placebo    zolpidem  0.1313 0.2100     0.2100     0.2590     2         
114          placebo    zolpidem  0.2812 0.1426     0.1426     0.2081     2         
120      eszopiclone     placebo -0.1576 0.1385     0.1385     0.2053     2         
122          placebo   zopiclone -0.0800 0.3820     0.3820     0.4110     2         
128 BZD-intermediate    zolpidem -0.0270 0.1590     0.1590     0.2197     2         
132          placebo   trazodone  0.1862 0.1466     0.1787     0.2577     3        *
132        trazodone    zolpidem  0.0629 0.1487     0.1840     0.2613     3        *
132          placebo    zolpidem  0.2490 0.1463     0.1781     0.2573     3        *
136      eszopiclone     placebo -0.2974 0.0738     0.0738     0.1686     2         
137          placebo    zolpidem  0.7851 0.1472     0.1472     0.2113     2         
144      eszopiclone     placebo -0.0462 0.1253     0.1253     0.1966     2         
145          placebo   ramelteon  0.0163 0.1218     0.1218     0.1944     2         
153      lemborexant    zolpidem  0.1066 0.0772     0.0865     0.2036     3        *
153          placebo    zolpidem  0.3262 0.0955     0.1400     0.2263     3        *
153      lemborexant     placebo -0.2195 0.0841     0.0978     0.2108     3        *
154      lemborexant     placebo -0.5557 0.1827     0.1827     0.2374     2         
155      lemborexant     placebo -0.0737 0.0688     0.0688     0.1664     2         
158          placebo seltorexant  0.2708 0.1383     0.1546     0.2412     3        *
158          placebo    zolpidem  0.2072 0.1699     0.2662     0.3044     3        *
158      seltorexant    zolpidem -0.0635 0.1401     0.1574     0.2437     3        *
160     daridorexant     placebo -0.0343 0.0805     0.0805     0.1716     2         

Number of treatment arms (by study):
    narms
2       2
6       2
10      2
12      2
39      2
45      2
46      2
58      2
59      2
60      2
61      2
63      2
75      2
77      2
83      2
99      3
105     2
112     2
114     2
120     2
122     2
128     2
132     3
136     2
137     2
144     2
145     2
153     3
154     2
155     2
158     3
160     2

Results (fixed effects model):

              treat1      treat2     SMD             95%-CI     Q leverage
2            placebo    zolpidem  0.3589 [ 0.2917;  0.4262] 21.68     0.07
6        eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  2.03     0.16
10           placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  2.99     0.10
12       eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  0.01     0.01
39           placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.52     0.05
45           placebo  suvorexant  0.1939 [ 0.0767;  0.3111]  0.23     0.52
46           placebo  suvorexant  0.1939 [ 0.0767;  0.3111]  0.25     0.48
58       eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  0.16     0.24
59           placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  3.79     0.26
60           doxepin     placebo -0.1881 [-0.3575; -0.0186]  1.23     0.23
61           doxepin     placebo -0.1881 [-0.3575; -0.0186]  2.01     0.34
63           doxepin     placebo -0.1881 [-0.3575; -0.0186]  0.20     0.42
75           placebo   ramelteon -0.0600 [-0.2061;  0.0860]  0.24     0.63
77       eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  0.48     0.10
83  BZD-intermediate     placebo -0.4935 [-0.7841; -0.2028]  2.35     0.17
99      daridorexant    zolpidem  0.2367 [ 0.0909;  0.3826]  2.92        .
99           placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.44        .
99      daridorexant     placebo -0.1222 [-0.2564;  0.0120]  0.58        .
105          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.30     0.06
112          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  1.17     0.03
114          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.30     0.06
120      eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  0.29     0.09
122          placebo   zopiclone -0.0800 [-0.8288;  0.6687]  0.00     1.00
128 BZD-intermediate    zolpidem -0.1345 [-0.4199;  0.1508]  0.46     0.84
132          placebo   trazodone  0.2395 [-0.0139;  0.4929]  0.09        .
132        trazodone    zolpidem  0.1194 [-0.1342;  0.3731]  0.09        .
132          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.38        .
136      eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  0.79     0.30
137          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  8.38     0.05
144      eszopiclone     placebo -0.2319 [-0.3112; -0.1525]  2.20     0.10
145          placebo   ramelteon -0.0600 [-0.2061;  0.0860]  0.39     0.37
153      lemborexant    zolpidem  0.1735 [ 0.0717;  0.2753]  0.60        .
153          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.05        .
153      lemborexant     placebo -0.1854 [-0.2768; -0.0940]  0.12        .
154      lemborexant     placebo -0.1854 [-0.2768; -0.0940]  4.11     0.07
155      lemborexant     placebo -0.1854 [-0.2768; -0.0940]  2.64     0.46
158          placebo seltorexant  0.3453 [ 0.1266;  0.5639]  0.23        .
158          placebo    zolpidem  0.3589 [ 0.2917;  0.4262]  0.32        .
158      seltorexant    zolpidem  0.0137 [-0.2052;  0.2325]  0.24        .
160     daridorexant     placebo -0.1222 [-0.2564;  0.0120]  1.19     0.72

Results (random effects model):

              treat1      treat2     SMD             95%-CI
2            placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
6        eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
10           placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
12       eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
39           placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
45           placebo  suvorexant  0.1952 [-0.0453;  0.4358]
46           placebo  suvorexant  0.1952 [-0.0453;  0.4358]
58       eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
59           placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
60           doxepin     placebo -0.1941 [-0.4369;  0.0488]
61           doxepin     placebo -0.1941 [-0.4369;  0.0488]
63           doxepin     placebo -0.1941 [-0.4369;  0.0488]
75           placebo   ramelteon -0.0499 [-0.3076;  0.2077]
77       eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
83  BZD-intermediate     placebo -0.5312 [-0.9162; -0.1461]
99      daridorexant    zolpidem  0.1656 [-0.0953;  0.4264]
99           placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
99      daridorexant     placebo -0.1760 [-0.4235;  0.0714]
105          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
112          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
114          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
120      eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
122          placebo   zopiclone -0.0800 [-0.8856;  0.7255]
128 BZD-intermediate    zolpidem -0.1896 [-0.5659;  0.1868]
132          placebo   trazodone  0.2318 [-0.1321;  0.5957]
132        trazodone    zolpidem  0.1098 [-0.2543;  0.4739]
132          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
136      eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
137          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
144      eszopiclone     placebo -0.2146 [-0.3613; -0.0678]
145          placebo   ramelteon -0.0499 [-0.3076;  0.2077]
153      lemborexant    zolpidem  0.1114 [-0.1022;  0.3249]
153          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
153      lemborexant     placebo -0.2302 [-0.4276; -0.0328]
154      lemborexant     placebo -0.2302 [-0.4276; -0.0328]
155      lemborexant     placebo -0.2302 [-0.4276; -0.0328]
158          placebo seltorexant  0.3373 [-0.0033;  0.6779]
158          placebo    zolpidem  0.3416 [ 0.2287;  0.4545]
158      seltorexant    zolpidem  0.0043 [-0.3365;  0.3451]
160     daridorexant     placebo -0.1760 [-0.4235;  0.0714]

Number of studies: k = 32
Number of pairwise comparisons: m = 40
Number of observations: o = 11458
Number of treatments: n = 12
Number of designs: d = 14

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI      z  p-value
BZD-intermediate -0.4935 [-0.7841; -0.2028]  -3.33   0.0009
daridorexant     -0.1222 [-0.2564;  0.0120]  -1.78   0.0744
doxepin          -0.1881 [-0.3575; -0.0186]  -2.18   0.0296
eszopiclone      -0.2319 [-0.3112; -0.1525]  -5.73 < 0.0001
lemborexant      -0.1854 [-0.2768; -0.0940]  -3.97 < 0.0001
placebo                .                  .      .        .
ramelteon         0.0600 [-0.0860;  0.2061]   0.81   0.4204
seltorexant      -0.3453 [-0.5639; -0.1266]  -3.09   0.0020
suvorexant       -0.1939 [-0.3111; -0.0767]  -3.24   0.0012
trazodone        -0.2395 [-0.4929;  0.0139]  -1.85   0.0639
zolpidem         -0.3589 [-0.4262; -0.2917] -10.46 < 0.0001
zopiclone         0.0800 [-0.6687;  0.8288]   0.21   0.8341

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value             95%-PI
BZD-intermediate -0.5312 [-0.9162; -0.1461] -2.70   0.0069 [-1.0433; -0.0191]
daridorexant     -0.1760 [-0.4235;  0.0714] -1.39   0.1632 [-0.5831;  0.2310]
doxepin          -0.1941 [-0.4369;  0.0488] -1.57   0.1173 [-0.5980;  0.2099]
eszopiclone      -0.2146 [-0.3613; -0.0678] -2.87   0.0042 [-0.5635;  0.1343]
lemborexant      -0.2302 [-0.4276; -0.0328] -2.29   0.0223 [-0.6058;  0.1453]
placebo                .                  .     .        .                  .
ramelteon         0.0499 [-0.2077;  0.3076]  0.38   0.7040 [-0.3641;  0.4640]
seltorexant      -0.3373 [-0.6779;  0.0033] -1.94   0.0523 [-0.8132;  0.1386]
suvorexant       -0.1952 [-0.4358;  0.0453] -1.59   0.1117 [-0.5977;  0.2073]
trazodone        -0.2318 [-0.5957;  0.1321] -1.25   0.2118 [-0.7265;  0.2628]
zolpidem         -0.3416 [-0.4545; -0.2287] -5.93 < 0.0001 [-0.6762; -0.0070]
zopiclone         0.0800 [-0.7255;  0.8856]  0.19   0.8456 [-0.8240;  0.9841]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0230; tau = 0.1516; I^2 = 62.4% [42.6%; 75.4%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f.  p-value
Total           66.47   25 < 0.0001
Within designs  54.30   18 < 0.0001
Between designs 12.17    7   0.0950
[1] "A total of 12 treatments are included in the network."
[1] "A total of 32 studies are included in this analysis."
[1] "A total of 11458 participants are included in this analysis."
[1] "The following studies were included in this analysis: 2 6 10 12 39 45 46 58 59 60 61 63 75 77 83 99 105 112 114 120 122 128 132 136 137 144 145 153 154 155 158 160"
[1] "Estimated heterogeneity tau-squared0.02"
[1] "Global test for inconsistency, p-value 0.09505 (Q=12, d.o.f. 7)"
[1] "File created on 2022-06-01"
